|
Tri-I TDI gains AlivaMab Mouse license
February 2017
SHARING OPTIONS:
BURLINGAME, Calif.—Ablexis LLC and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) have struck up a non-exclusive, perpetual license agreement for access to the
AlivaMab Mouse for antibody drug discovery and development. With this deal, the Tri-I TDI gains its own colony of AlivaMab Mouse and broad rights to use it
for antibody drug discovery and development. The Tri-I TDI is an initiative by Memorial Sloan Kettering
Cancer Center, The Rockefeller University and Weill Cornell Medicine that discovers small molecules and biologics for proof-of-concept studies. Financial details were not
disclosed.
“This agreement with Ablexis opens up new opportunities for innovation in our community,” said Tri-I
TDI CEO Dr. Michael Foley. “We are delighted that the AlivaMab Mouse platform can now be applied to the breakthrough scientific findings of our
investigators to discover new drugs. This has the potential to accelerate the rate with which we can bring new therapies to patients.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|